Noze will further the impact of its unique
technology with support from the Bill & Melinda Gates
Foundation
MONTREAL, March 28, 2024 /PRNewswire/ -- Canadian-based
Noze, a global leader in the breath-based diagnostic space,
announced today it received a new grant from the Bill & Melinda
Gates Foundation, bringing the foundation's total grant funding to
Noze to $1.8 million. The
announcement comes on the heels of World Tuberculosis Day, which
was recognized on March 24th.
The grant will fund a groundbreaking clinical study aimed at
detecting tuberculosis (TB) in high-burden countries, using the
company's DiagNoze® — a handheld breathalyzer designed for the
real-time detection and screening of various medical conditions,
including infectious diseases such as TB. The cost-effective and
rapid results offered by DiagNoze® are poised to shorten
the time to diagnosis, facilitate earlier intervention, and
significantly improve patient outcomes. Ultimately, the goal is for
Noze to help enable universal access and play a vital role in the
global fight against the spread of TB.
"We're thrilled to receive additional funding from the Bill
& Melinda Gates Foundation. This new grant will support Noze's
capacity to profoundly influence the management and eradication of
infectious diseases," noted Karim
Aly, CEO of Noze.
The World Health Organization reports that TB infects about 10
million people annually, with 1.5 million fatalities, making it the
deadliest infectious disease globally. Even more troubling is that
TB is both preventable and treatable, yet in low and middle-income
countries—where the disease is most prevalent—screening options are
hindered by limited availability, high costs, and an absence of
rapid results.
"The power of our technology is in its unique ability to
transcend geographical and economic boundaries, enabling even the
most remote and underserved communities to benefit from diagnostic
capabilities that were once exclusive to major health systems," Aly
explained. "The ability to perform high-yield, low cost screening
of tuberculosis is a critical driver in ending the global epidemic.
Faster, broader screening means earlier diagnosis and timely
treatment, which results in less spread and fewer lives lost."
With the second grant in place, Aly noted he expects the
clinical study to begin in the fall of 2024.
About Noze: Noze is the global leader in digital odor
perception (often hailed as the digital equivalent of the sense of
smell). They have developed the world's most advanced digital nose,
capable of detecting and identifying odors in real-world settings
with unparalleled accuracy. Leveraging cutting-edge machine
intelligence and a sensor developed with exclusively licensed NASA
technology, Noze is committed to enhancing human health and
wellbeing. Their mission is to improve patient outcomes by enabling
real-time disease detection at any point-of-care by using their
technology to target breath-based odor biomarkers. For more
information, visit noze.ca.
Media contact: Corrie A.
Fisher
Email: Noze@KNBComm.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/canadian-medtech-startup-amplifies-fight-against-tuberculosis-with-new-grant-302101755.html
SOURCE Noze